Xista is a science ventures company that focuses on seed investments in transformative technologies across Europe.

xista science ventures

Xista

We invest in visionary science start-ups. As part of the xista ecosystem, set up by the Institute of Science and Technology Austria, xista science ventures speak the language of scientist and investor. This makes us a unique partner to fuel founders’ deep tech ideas and help build exciting, scalable companies.

Our understanding of academic spin-offs and the deep tech founders landscape, allows xista science ventures to recognise, analyse and propel companies to the next stage. We encourage the cross-fertilisation of startups to inspire new discoveries. Let us learn and profit from each other.

Using AI to Power the Cleantech Transition
Our Venture Partner, Bernhard Petermeier, was featured in Cleantech for Europe’s Voices of Innovation series: 

“AI is a remarkably sharp tool for transforming resource-hungry industries, products, and services by providing data-driven suggestions or making decisions.”

𝐀𝐭 𝐱𝐢𝐬𝐭𝐚 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐯𝐞𝐧𝐭𝐮𝐫𝐞𝐬, 𝐨𝐮𝐫 𝐩𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐚𝐫𝐞 𝐥𝐞𝐯𝐞𝐫𝐚𝐠𝐢𝐧𝐠 𝐀𝐈 𝐢𝐧 𝐝𝐢𝐯𝐞𝐫𝐬𝐞 𝐬𝐜𝐞𝐧𝐚𝐫𝐢𝐨𝐬 𝐭𝐨 𝐝𝐫𝐢𝐯𝐞 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐥𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧:
Prewave: Supply Chain Risk Monitoring
infrared.city: Environmental Simulations
nista.io: Energy Analysis and Consumption Optimization
subdron: Underwater Infrastructure Management

➡️ Read the full article: https://lnkd.in/ezkKMixz 

#AI #Cleantech #Sustainability #Innovation #xista #CleantechForEurope

🎉 Congratulations to Cutanos GmbH on winning the prestigious 𝗕𝗔𝗥𝗗𝗔 𝗩𝗜𝗧𝗔𝗟 𝗣𝗿𝗶𝘇𝗲 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲!

This award is a testament to the impact you’re making in 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀.

Here's to more milestones and continued success! 

Cutanos is dedicated to developing next-generation vaccines incorporating its proprietary Langerhans Cell Targeting (LC-TDS) Technology. Looking ahead, the company will increase its efforts towards infectious diseases, capitalizing on the advantages of its technology to boost the efficacy and stability of mRNA vaccines, as well as high patient compliance due to pain-free skin administration.

More information on Cutanos:
www.cutanos.com

More information on Barda Vital Prize:
https://lnkd.in/dmJWY-nq


#ProudInvestor #Innovation #Success #Congratulations #VentureCapital

Securing €63 million in its Series B funding round, Prewave reaches the next milestone in it's remarkable growth journey. Led by Hedosophia, this funding highlights the promising future of the company, that aims to leverage AI to help businesses manage unprecedented supply chain challenges and deliver the world’s first supply chain superintelligence platform. 

We at xista science ventures are proud to support the Prewave as an early-stage investor, alongside new and existing investors.
 
Key Takeaways:

🌍 New regulations are significantly increasing supply chain reporting and compliance requirements for businesses, amid growing global uncertainty.

🔍 Prewave's AI driven supply chain risk intelligence platform is used by customers including Toyota, Ferrari and Dr Oetker.

💡This new funding will fuel global expansion and support further product R&D.

Read the full press release: https://lnkd.in/dYF-3juH
 
About Prewave:
Prewave is the future-ready sustainability, risk and compliance platform. Its best-in-class AI technology delivers an intelligent solution to businesses’ pressing supply chain challenges. Over 200 global companies including Toyota, Ferrari and Dr Oetker use Prewave to make their supply chains compliant and increase their overall resilience and sustainability. 

Founded in 2017, Prewave’s investors include Hedosophia, Creandum, Ventech, KOMPAS VC, Speedinvest, Working Capital Fund, seed + speed Ventures, SEGNALITA Ventures GmbH, xista science ventures and aws Gründerfonds Equity Invest GmbH & Co KG.

➡️ Find out more: www.prewave.com

#VentureCapital #Startups #SustainableBusiness #SupplyChainManagement

Syntropic has been recognized as a 2024 Health graduate of the esteemed Creative Destruction Lab (CDL), positioning itself as a frontrunner in health innovation.

Syntropic Medical is the latest addition to the xista science ventures portfolio. The pre-clinical stage medical device company is dedicated to developing new technologies that enhance the brain’s neuroplasticity, allowing for the treatment of psychiatric disorders and the improvement of cognition.

Find out more on their website: www.syntropicmedical.com 
#startup #scaleup #entrepreneurship #investment #BuildSomethingMassive

With a whopping 4.500 applicants for only 70 available slots, the 9th edition of the renowned Deep Tech Startup Competition, Hello Tomorrow, was anything but boring. Classified into one of 10 categories, two of xista science ventures' portfolio companies were nominated as finalists, competing against 6 other equally impressive startups in their field.

Cellectric Biosciences emerged as the best in the category of Digital Health & Medical Devices with their platform for automated electromagnetic cell manipulation. Their technology provides a novel, complexity-reducing approach in the fight against sepsis-caused mortality.

VitreaLab was nominated in the category of Advanced Computing & Electronics, showcasing their quantum-photonic technology-inspired laser-based displays for augmented reality and virtual reality. A technology that offers higher brightness, color gamut, and significantly lower energy consumption than competing technologies.

Want to know more? Find the Websites of Cellectric and Vitrealab in the first comment.

📷 Klemens Wassermann © Léo Coulongeat
📷 Chiara Greganti ©Léo Coulongeat

#cellectric #electrome #sepsis #Vitrelab #AR #VR #laser #hellotomorrow #deeptech

Two xista portfolio companies are exhibiting at Innovation Corner at Technisches Museum Wien mit Österreichischer Mediathek. 

We are proud to announce that VALANX Biotech and Syntropic were selected to present their technologies at Innovation Corner, an exhibition highlighting exciting innovation in Lower Austria. This week, we kicked off the exhibition together with Governor Mikl-Leitner and organizers tecnet equity and accent Inkubator GmbH. Check out the Innovation Corner until September 29th.

About Syntropic Medical
Syntropic Medical showcase their prototype for the treatment of psychiatric disorders. Using high-frequency light pulses emitted by their goggle-like medtech device, Syntropic Medical addresses the need for non-pharmacological treatments for psychiatric disorders such as depression. 
➡️Find out more: https://lnkd.in/egnvEKwW

About VALANX Biotech 
VALANX turned their protein conjugation platform into a video game. 
The site-specific protein conjugation platform of VALANX Biotech is used to exert precise control over the conjugation site and number of conjugations of their protein conjugates. Using a synthetic amino acid, they develop protein conjugates optimized for stability, low aggregation, efficacy, therapeutic window, and low immunogenicity. 
➡️Find out more: https://www.valanx.bio/

#xista #Innovation #Biotech #ViennaInnovation #HealthcareInnovation #FutureOfMedicine

XIST

VC:XISTA

Xista

name

homepage url

country

linkedin url

employee count

sector

industry

Description

invested in

Metrics